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REVIEW
Gut microbes and metabolites as modulators of blood-brain barrier integrity
and brain health
Aimée Parker*a, Sonia Fonseca*a, and Simon R. Cardinga,b
aGut Microbes and Health Research Programme, Quadram Institute Bioscience, Norwich, UK; bNorwich Medical School, University of East
Anglia, Norwich, UK
ABSTRACT
The human gastrointestinal (gut) microbiota comprises diverse and dynamic populations of
bacteria, archaea, viruses, fungi, and protozoa, coexisting in a mutualistic relationship with the
host. When intestinal homeostasis is perturbed, the function of the gastrointestinal tract and other
organ systems, including the brain, can be compromised. The gut microbiota is proposed to
contribute to blood-brain barrier disruption and the pathogenesis of neurodegenerative diseases.
While progress is being made, a better understanding of interactions between gut microbes and
host cells, and the impact these have on signaling from gut to brain is now required. In this
review, we summarise current evidence of the impact gut microbes and their metabolites have on
blood-brain barrier integrity and brain function, and the communication networks between the
gastrointestinal tract and brain, which they may modulate. We also discuss the potential of
microbiota modulation strategies as therapeutic tools for promoting and restoring brain health.
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Introduction
The gut microbiota play an essential role in the
functioning of many organs in the body, including
the brain. Our understanding of the composition
and metabolism of the diverse ecosystem populat-
ing the gut, and the complex communication net-
works comprising the gut-brain axis are rapidly
increasing in hand with advances in high-
throughput ‘omics-based technologies. This review
summarises findings linking the gut microbiota
and brain health, with a focus on the impact of
gut microbes, and the metabolites they generate
from dietary components, on blood-brain barrier
integrity. We discuss how these metabolites travel
throughout the body along bidirectional neural
and circulatory routes, from the perspective of
the current knowledge of specific mechanisms.
We also highlight the potential therapeutic poten-
tial on brain health of manipulating the gut micro-
biota via delivery of prebiotics, probiotics, and
fecal microbiota transplantation. Such approaches
can be effective in treating gastrointestinal disor-
ders, and while their suitability and efficacy to
treat neurological and neurodegenerative condi-
tions require investigation, they are promising
tools that may open unexplored routes to disease
treatment and prevention through precise micro-
biome-targeted therapies.
The intestinal microbiota in health and
neurodegenerative diseases
The human microbiota consists of a diverse and
dynamic population of microbes, including bac-
teria, archaea, viruses, fungi, and protozoa, that
establish a mutualistic relationship with the host.
More than 1014 bacteria cells populate the gastro-
intestinal (GI) tract the vast majority of which
(1010–1012 CFU/g of intestinal content) are located
in the ileum and colon.12 A taxonomically diverse
intestinal microbiota is associated with integrity of
the epithelial barrier, and maintenance of intest-
inal metabolic and immune homeostasis. Some
species of Lactobacillus and Bifidobacterium gen-
era are considered beneficial, with the presence of
Lactobacillus rhamnosus, for example, associated
with increased intestinal barrier function and
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expression of epithelial tight junction proteins, and
decreased serum levels of inflammatory cytokines.3
By comparison, overgrowth of Clostridium is often
a feature of intestinal microbial dysbiosis and
increased intestinal permeability (“leaky gut syn-
drome”), a feature of inflammatory bowel diseases
and other immune-related intestinal and extra-
intestinal disorders.4 Beyond the GI-tract, the
microbiota may also play a role in the functioning
of other organ systems including the brain.5
Evidence for the GI-microbiota influencing the
brain comes primarily from animal studies, in
particular germ-free rodents, in which structural
and functional attributes of the brain can be
assessed prior to, and after, microbial exposure
and colonization. The absence of gut microbes is
associated with structural alterations in the blood-
brain barrier (BBB), characterized by decreased
expression of tight junction proteins, leading to
increased permeability compared to conventional-
specific pathogen free (SPF) mice.6 Of note, con-
ventionalizing germ-free mice using fecal material
from SPF mice, decreases the permeability of the
BBB,6 providing evidence of a causal relationship
between gut microbes and BBB integrity. Related
experiments using chronically-administered anti-
biotics to deplete the gut microbiota in mice
resulted in object recognition impairment7 and
decreased hippocampal neurogenesis and memory
retention, which were reversed by administering
probiotic bacteria.
Recent studies suggest the gut microbiota may
contribute to the development or progression of
neurodegenerative diseases and dementia.
Neurodegenerative diseases are characterized by
impaired motor function and/or dementia, which
is one of the major causes of disability and depen-
dency among older people worldwide.8 Dementia
is a collection of symptoms used to categorize and
diagnose the disease type. Common forms include
Alzheimer’s disease (AD), vascular dementia, fron-
totemporal dementia, Parkinson’s disease (PD),
and dementia with Lewy bodies; all are chronic
or progressive in nature and feature deterioration
in memory, thinking, behavior, and the ability to
perform everyday activities. A common feature of
all dementias is chronic neuroinflammation, invol-
ving overactivation and dysregulation of
microglia,9 the resident macrophage-like immune
cells of the brain. When microglia are activated,
their morphology changes in association with
increased secretion of pro-inflammatory cytokines,
such as IFN-γ, IL-6, and TNF-α, and the release of
reactive oxygen and nitrogen species,10 which can
lead to neuronal cell death, loss of BBB integrity,
and brain damage. Whether changes in BBB integ-
rity are a cause or a consequence of neuroinflam-
mation in patients is a major unresolved
question.11 This central question has been
approached using animal models and, in particu-
lar, genetically modified mice which develop fea-
tures of AD or PD. Transgenic mice expressing the
amyloid-β precursor protein (APP) develop fewer
cerebral β-amyloid plaques when maintained
under germ-free conditions compared to conven-
tionalized mice.12 Consistent with this finding, and
supporting a role for the gut microbiota in the
pathogenesis of neuroinflammation in this mouse
model, antibiotic administration also limits β-
amyloid pathology and neuroinflammation.13
Possible links between specific commensal bacteria
and neuroinflammation have been identified from
microbiota taxonomic profiling in PD patients
with alterations in populations of potentially ben-
eficial bacteria (e.g. Prevotella genus) and patho-
genic bacteria (e.g. members of the
Enterobacteriaceae family).14,15 Although these
findings are intriguing and implicate the gut
microbiota in neuroinflammation, they and other
related studies have, to date, provided limited
mechanistic insight and have been unable to iden-
tify the pathways by which gut microbes can influ-
ence, directly or indirectly, the BBB.
The blood-brain barrier
The term “blood-brain barrier” was first coined by
Stern and Gautier,16 who examined the penetra-
tion or exclusion of compounds, such as morphine
or India ink, between blood and brain, and pro-
posed a role for the barrier in maintaining brain
homeostasis. Later studies in the 1960s demon-
strated that the BBB was located in the endothe-
lium forming the walls of vessels in the brain.17,18
Since these pioneering studies, the concept of the
BBB as a static, impermeable barrier has evolved
into the current view of a dynamic, highly regu-
lated, specific cellular system,19 with increasing
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awareness of the contribution multiple cell types
play in regulating dynamic BBB responses. The
BBB is now considered to be part of
a neurovascular unit (NVU) (Figure 1) comprising
brain microvascular endothelial cells (BMEC),
pericytes, astrocytes, neurons, microglia, and
extracellular matrix (ECM),20 which together con-
tribute to regulating BBB stability and function.
This organization is found in all brain regions,
except for the circumventricular organs, which
regulate the autonomic nervous system and endo-
crine glands and have fenestrations allowing the
diffusion of molecules across vessel walls.21
BMECs are interconnected by protein complexes
consisting of highly electrically-resistant tight junc-
tions (zonulae occludens), which limit the paracellular
flow of molecules between adjacent endothelial cells
to maintain ionic homeostasis in the brain.22 Joining
the BMECs are several non-endothelial cells including
pericytes that wrap around the capillary
endothelium23 and can modify vascular diameter
and regulate transcytosis and immune cell trafficking
across the BBB.24 Astrocytes and their endfeet form
a second physical, transport, and metabolic barrier
around pericytes and endothelial cells, and commu-
nicate with neurons to establish an endothelium-
neuron link.25 Pericytes and astrocytes also transmit
neuronal signals to the local vasculature, affecting
barrier physiology by altering arteriolar dilation and
blood flow.26 While implicated in the regulation of
vascular growth during angiogenesis, the role of
microglia in homeostatic BBB maintenance is not
clear, but these cells are major players in the inflam-
mation associated with neurodegenerative diseases,
secreting pro-inflammatory cytokines and factors
promoting BBB breakdown and neuronal loss. In
inflammatory states, remodeling of BMEC tight junc-
tions increases transcellular permeability, allowing
circulating inflammatory cytokines and effectors into
the brain. Inflammatory activation of vascular
endothelium can induce BMEC expression of adhe-
sion molecules and chemoattractants, allowing infil-
tration of neutrophils and effector Th1 and Th17
subsets of CD4+ T cells which are implicated in the
pathogenesis of multiple sclerosis (MS), AD and
PD.27,28 Astrocyte morphology and secretion of
inflammatory cytokines and chemoattractants are
altered in early stages of AD pathology.26 Amyloid-β
protein can induce BMEC activation and tight junc-
tion remodeling, and pericyte damage and loss leads
to cognitive impairment, increased amyloid-β deposi-
tion, and tau pathology.29 In summary, a combination
of inflammation and changes in BBB component cell
functions contribute to neurodegenerative disease-
associated BBB breakdown. Infiltrating immune
cells, microglial cells, and astrocytes may reciprocally
activate each other, driving chronic inflammation and
preventing BBB repair, with pericyte damage and
neuronal loss further promoting cognitive decline.
Preserving and restoring BBB integrity therefore
Figure 1. Schematic representation of the human blood-brain-barrier neurovascular-endothelial-unit in health (a) and disease (b)
states. Increased permeability related to, for example trauma or infection, is associated with disruption of endothelial tight junctions
leading to the ingress and translocation of blood-borne immune cells, and inflammatory mediators such as cytokines and microbes
and their products that can activate microglia, resulting in local inflammation leading to loss of extracellular matrix and astrocyte,
pericyte and neuronal cell dysfunction and death.
GUT MICROBES 3
presents a primary target for developing neuroprotec-
tive strategies and interventions.
Gut microbiota-derived metabolites
influencing BBB integrity and brain health
The gut microbiota transform dietary components,
including macro- and micronutrients, fibs, and
polyphenols, into a range of metabolites, including
short-chain fatty acids, trimethylamines, amino
acid derivatives, and vitamins. These microbial-
derived metabolites and dietary components have
essential metabolic and signaling functions which
can modulate host homeostasis, including BBB
integrity and brain function. Microbial metabolites
affecting the BBB and brain are detailed below,
and specific studies describing effects of some of
these metabolites on BBB permeability are sum-
marised in Table 1.
Short Chain Fatty Acids (SCFA): are small
organic monocarboxylic acids, principally produced
by colonic fermentation of dietary fib and complex
plant-based polysaccharides, to generate energy and
release carbon, permitting microbial growth. SCFAs
are present at an approximate concentration of
100 mM in the colonic lumen at a ratio of 60:25:15
for acetate:propionate:butyrate, respectively.34 The
production of propionate is primarily restricted to
members of the Clostridiales order of anaerobic bac-
teria, with production of acetate and butyrate being
more broadly distributed.35 Over 95% of SCFAs
produced in the colon are absorbed by the mucosa
of healthy individuals36 with all three detectable in
the peripheral blood at ratios different to those in the
lumen (acetate, 22–42 μM; propionate, 0.9–1.2 μM;
butyrate, 0.3–1.5 μM).33 SCFAs stimulate colonic
blood flow, upper-gut motility, influence water and
salt uptake, and enhance satiety.36 They can also
access the BBB via the bloodstream to impact
directly on its integrity.37 For example, BBB perme-
ability decreases in germfree mice after colonization
with the butyrate producer Clostridium tyrobutyri-
cum or, after oral administration of sodium butyrate,
by upregulating tight junction proteins.6 Following
traumatic brain injury, intravenous or intraperito-
neal administration of sodium butyrate can prevent
BBB breakdown and promote neurogenesis.30,31,38 It
is therefore conceivable that modulating SCFA levels
could be useful in preventing or treating neural
decline. Intraperitoneal administration of butyrate
or increased dietary soluble fib (inulin) intake
improve neuroinflammation in aging mice,39 and
in CK-p25 transgenic mice, which exhibit synaptic
and neuronal loss and learning, intracerebroventri-
cular injections of butyrate modify histone acetyla-
tion in the hippocampus to improve memory and
learning.40 Protective, anti-inflammatory, and per-
meability-reducing effects of propionate treatment
have also been described in a human brain endothe-
lial cell culture model.33 On the other hand, high
brain levels of propionate can exacerbate symptoms
in a mouse model of autism, but this can be miti-
gated with butyrate supplementation,41 suggesting
metabolite balance rather than individual metabolite
levels may be important. The maturation of micro-
glial cells, which regulate BBB integrity, neuroin-
flammation, and neurogenesis, is modified by
SCFA in germfreemice, where the reducedmicroglia
number, function and morphology can be rescued
by 4-week delivery of an SCFA cocktail in drinking
water.42 Pending clinical trials on specific-optimized
SCFA supplementations, it has been hypothesized
Table 1. Effects of gut microbes and their metabolites on blood-brain barrier permeability.
Method Permeability modulator Model Effects on BBB Reference
In vivo Clostridium butyricum Traumatic brain injury on C57Bl/6 mice ↑ TJ proteins expression
↓ Permeability
30
Clostridium tyrobutyricum,
Bacteroides thetaiotaomicron and sodium
butyrate
Germ-free C57Bl/6 mice ↑ TJ proteins expression
↓ Permeability
6
Sodium butyrate Traumatic brain injury on C57Bl/6 mice ↑ TJ proteins expression
↓ Permeability
31
Acetate/propionate/butyrate α-synuclein overexpressing germ-free BDF1
mice
↑ Microglia activation 15
Chenodeoxycholic acid and deoxycholic acid Bile duct ligation on Sprague Dawley rats ↑ Permeability 32
In vitro Propionate hCMEC/D3 treated with LPS ↓ Paracellular permeability
↑ TEER
33
Chenodeoxycholic acid and deoxycholic acid RBMECs ↑ Permeability 32
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that providing SCFA mixtures or simply increasing
dietary fib could rescue the hypometabolism asso-
ciated with neuronal dysfunction in neurodegenera-
tive conditions including AD.43 Intriguingly,
a handful of recent studies in which bacterial, viral,
and fungal-derived nucleic acids and proteins have
been detected in post-mortem brains of AD
sufferers44,45 suggest microbial metabolites such as
SCFAs could be produced locally, by brain-resident
or infiltrating microbes. The possibility of a ‘brain
microbiome’ remains controversial, but while con-
sideration of possible contamination issues is needed
in interpreting the detection of nucleic acids from
low-abundance microbes in tissue samples, Carrasco
and colleagues46-48 provide supporting immunos-
taining data for various fungal species in post-
mortem brain tissue from Alzheimer’s patients.
These included Candida albicans, which is com-
monly found in the mammalian gut but more rarely
isolated from the environment,49,50 and the detection
of both budding and hyphal forms,47,48 indicative of
fungal growth within the living tissue. Whilst gut
microbes can dictate the metabolite availability
within the intestine and the brain via the circulation,
whether they have a significant impact on SCFA
availability within the brain as ‘local’ residents
remains to be determined. Additional work is now
needed to understand the optimum balance of
SCFAs in the periphery and the brain which pro-
mote healthy aging, and further still how the micro-
biome of the gut (and potentially the brain) can be
manipulated to achieve this balance and protect cog-
nitive health.
Trimethylamines: are metabolites produced from
gut microbial metabolism of dietary choline,
lecithin, carnitine and trimethylamine-N-oxide
(TMAO) that are present in foods such as eggs,
nuts, dairy products, meat, and fish. Choline is
degraded into trimethylamine (TMA), which is con-
verted in the liver by flavin-containing monooxy-
genases (FMOs) into TMAO, and demethylated into
dimethylamine and methylamine.51 Gut-derived
TMA is generated by bacteria of the genera
Anaerococcus, Clostridium, Escherichia, Proteus,
Providencia, and Edwardsiella.52 The presence of
TMAO in human brains indicates its ability to cross
the BBB.53 TMAs have been associated with both
beneficial and detrimental health effects. High plasma
levels of TMAO have been associated with increased
risk of colorectal cancer54 and with risk of developing
atherosclerosis and cardiovascular disease via effects
on cholesterol metabolism.55 This is of interest
regarding neurodegenerative diseases including AD
and vascular dementia, in which cardiovascular dis-
ease and altered cholesterol metabolism are strongly
associated with increased risk. In individuals with
a hereditary defect in FMO3, bacterial TMA produc-
tion contributes to the symptoms of trimethylami-
nuria (TMAU) or fish-odor syndrome.56 Therapy
with archaebiotics and attempting to modulate the
gut microbiota by administering specific strains of
TMA metabolizing Archaea has been proposed as
a treatment for cardiovascular diseases and TMAU.
The methanogen,Methanomassiliicoccales can reduce
TMA concentration in the gut by converting it to
methane, thus decreasing the production of TMAO
from TMA in the liver.57,58 TMAO’s beneficial effects
include reducing endoplasmic reticulum stress and
lipogenesis in adipocytes, increasing insulin secretion
in pancreatic islets, and attenuating diet-induced
impaired glucose tolerance.59,60 Again, by extension,
such therapies may also be beneficial in protecting
against neurodegenerative disease as diabetes which is
another dementia-associated risk-factor. More speci-
fic to AD, TMAO has also been shown to restore the
ability of mutant tau protein to promote microtubule
assembly61,62 with microtubule disassembly and neu-
ron death being hallmark pathological features
of AD.63 In addition to its potential use as an AD
biomarker,64 TMAO may also have a therapeutic
effect in AD and other protein-misfolding conditions,
by preferentially hydrating partially denatured pro-
teins to correct folding defects and entropically stabi-
lizing native conformations.65,66
Amino acid metabolites: the gut microbiota
plays an essential role in amino acid catabolism
the products of which can influence the balance
between the production of excitatory and inhibi-
tory neurotransmitters essential for correct brain
functioning.67 Species of the genera Lactobacillus
and Bifidobacterium metabolize glutamate, the
most abundant free amino acid and excitatory
neurotransmitter in the brain, to produce γ-
aminobutyric acid (GABA), a major inhibitory
neurotransmitter.68 Decarboxylases secreted by
Clostridium sporogenes contribute to converting
tryptophan, an essential amino acid found in
a wide range of foods,69 to the neurotransmitter
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tryptamine, involved in the release of serotonin by
cells of the enteroendocrine and enteric nervous
systems.70,71 Germfree mice display increased
plasma tryptophan levels, which are normalized
after conventionalization.72 Bifidobacterium infan-
tis can increase plasma levels of tryptophan.73
Bacterial conversion of tryptophan to indoles,
ligands for aryl hydrocarbon receptor (AHR), can
decrease brain inflammation and limit disease
severity in murine models of MS by activating
astrocytes.74 Tryptophan is a precursor of many
other diverse microbial and host metabolites75
including kynurenic acid, which has anti-
inflammatory properties in the gastrointestinal
tract76 and is considered to be neuroprotective,77
and quinolinic acid, which is a neurotoxin and
a BBB modulator implicated in the etiology of
psychiatric disorders and neurodegenerative
diseases.78,79 Tryptophan and glutamate-
metabolizing microbes may therefore perform
important BBB and brain-protective functions,
but greater understanding and care are needed to
harness their therapeutic potential while avoiding
the effects of potentially harmful derivatives.
Vitamins: are essential micronutrients which
humans must obtain from their diet and intestinal
microbiota. Vitamin K is produced by Escherichia
coli, Klebsiella pneumoniae, Propionibacterium, and
Eubacterium; B2 (riboflavin) by Bacillus subtilis and
E. coli; B9 (folic acid) by Bifidobacterium, Lactococcus
lactis and Streptococcus thermophilus; and B12 (coba-
lamin) by Lactobacillus reuteri and Propionibacterium
freudenreichii.80 The uptake of microbe-derived vita-
mins occurs predominantly in the colon, in contrast
to dietary vitamins, which are absorbed in the small
intestine.81 Vitamins have a variety of roles in main-
taining and protecting intestinal and systemic health
throughout life. Vitamin K, essential for the process of
thrombosis,82 is routinely administered to neonates
shortly after birth to prevent hemorrhagic disease,
prior to the establishment of their gut microbiota.83
Low levels of vitamin K have been correlated with
apolipoprotein Eε4 allele, a risk factor linked to AD.84
Vitamin K has also been shown to have a beneficial
role in the modulation of α-synuclein fibrillization,
associated with PD.85 Increased dietary vitamin
K intake has been associated with less severe subjec-
tive memory complaints in the elderly.86 Vitamin
B synthesis increases as the intestinal microbiota are
being established87 with deficiencies leading to serious
neurological disorders including beri-beri, polyneuro-
pathy and cerebellar ataxia.88 Vitamin B9 has
a preventive role in the development of neural tube
defects, coronary heart disease, cancer, and neurop-
sychiatric disorders.89 Folate deficiency has been asso-
ciated with depression, with methylfolate being one of
the only medical foods licensed for treating
depression.90,91 Folate intake below the
Recommended Daily Allowance may also increase
the risk for mild cognitive impairment and probable
dementia among older women.92 Similarly, high-dose
B-vitamin treatment, including B6, B9, and B12, can
decrease levels of homocysteine, a by-product of vita-
min B, and slow the atrophy of specific regions of the
brain associated with cognitive decline in AD.93
In summary, SCFAs and other microbial meta-
bolites can act at the intestinal epithelial barrier,
the blood-brain-barrier, directly on brain neurons,
or by regulating the endocrine and immune sys-
tems to protect against the pathology and inflam-
mation associated with ageing and disease, and
may also protect against neurodegeneration by
limiting the transit and influx of pathological
microbes and their products into the brain.
Pathways of communication along the
microbiota-gut-brain axis
Intestinal metabolic health status is relayed to the
brain by both neural and circulatory routes
(Figure 2). Bidirectional gut-brain neural relays con-
trol satiety signaling and appetite regulation.94
Detection of luminal metabolites by intestinal enter-
oendocrine cells is communicated to the brain via
activation of the vagus nerve,95 by epithelial cell-
derived hormones and neurotransmitters,96,97 and
via neural routes, including neuroepithelial
connections.98,99 Dietary metabolites and epithelial-
derived soluble factors may also travel via the
bloodstream to the BBB, where a variety of nutrient
transporters and specific receptors expressed on
BMECs100,101 facilitate the translocation of specific
nutrients (e.g. glucose, lactate) across the barrier into
the brain parenchyma, and allow for binding of circu-
lating peptide hormones and other factors which can
modulate brain activity. The microbial metabolites
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discussed above including SCFAs, TMAs, amino acid
metabolites, and vitamins can travel via or modulate
these pathways to affect enteroendocrine, neuronal,
and immune cells in the gut, liver, kidneys, pancreas,
and brain.
Endocrine and neuroendocrine signaling
In the intestinal epithelium, specialized sensory
enteroendocrine cells express a range of
G-protein-coupled receptors (GPCR), transpor-
ters, and other receptors for fatty acids, carbo-
hydrates, peptides, amino acids, and
phytochemicals. Binding of bacterial products
to these receptors induces the release of peptide
hormones (including the incretin hormones
GLP-1 and GIP, and neuropeptides CCK, PYY,
and serotonin) which can act locally on enteric
neurons, or enter the circulation and activate
neurons innervating the portal vein, to signal
to the brainstem via the vagus nerve. It is pos-
sible that some circulating hormones could reach
and act directly on the brain. GLP-1 for example
may be able to reach the brain either by crossing
the blood-brain barrier102 or by acting at cir-
cumventricular structures.103 However, the
short half-life of peptide hormones in the
circulation,104 the excitation of enteric neurons
and the vagus in response to metabolites and gut
hormones,105,106 and the speed of responses to
nutrients,107 reinforce the importance of neural
signaling networks in communicating signals
from the gut to the brainstem.108 Enteric neu-
rons express receptors for SCFAs109 and bile
acids110 facilitating metabolite regulation of gas-
trointestinal motility111 and allowing fast relay of
information to the brain about metabolites
crossing the epithelial barrier, and the concen-
trations of those metabolites in the gut lamina
propria. For example, administration of luminal
glucose activates both enteroendocrine cells and
neural cells of the myenteric plexus, nodose
ganglion and brainstem.112
Recent studies reveal direct physical associa-
tions between the epithelium and enteric
nerves. Some enteroendocrine cells exhibit
Figure 2. Pathways of communication along the gut-microbiota-brain axis. A complex interplay of epithelial, immune and neural cell
signalling networks is involved in sensing and communicating changes in microbial metabolites in the gut and the brain involving
both circulatory and neural routes.
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‘neuropod’ processes which directly synapse
with local neural networks, forming ‘neuroe-
pithelial units’ which can and transmit chemi-
cal and electrical signals in response to
metabolite binding.99,113 At present, the relative
balance and importance of the circulatory,
neural, and neuro-epithelial routes in relaying
luminal information to the brain are unknown.
Given the complexity within the gastrointest-
inal tract luminal environment, the summation
and combination of all routes may be required
to accurately convey varying spatiotemporal
conditions and fluctuating microbial and meta-
bolic states.
Encouragingly, the ability to map connectivity
between neurons manipulate neural activity in
real time, and measure neural activity during
behavior has produced a wealth of data approach-
ing a “wiring diagram” of the bidirectional gut-
brain control of appetite, able to describe and
predict the effects of dietary nutrients, common
hormones and regulators.94 Building on this,
recent studies are attempting to connect altered
bacterial metabolism to specific neural signaling
affecting brain functions. For example, Schretter
and colleagues114 describe how locomotor hyper-
activity in germfree Drosophila (manifested as
increased walking speed and daily activity) can
be rescued by altering sugar metabolism, either
by colonization with L. brevis or by administra-
tion of L. brevis-derived xylose isomerase. The
behavioral hyperactivity effect in germfree flies
was shown to be mediated by octapaminergic
neurons, as specific stimulation of these neurons
or exogenous administration of octopamine (the
invertebrate counterpart of noradrenaline) pre-
vented the rescue by xylose isomerase.114 In
mouse models, in vivo cell-connectivity tracing
and enteroendocrine-neural co-cultures have
shown that glucose stimulation of CCK-positive
enteroendocrine cells activates vagal nodose neu-
rons by glutamate-based neurotransmission.99
What impact this signaling might have on regula-
tion of BBB integrity and neurodegenerative dis-
ease remains to be determined, but it is an
exciting step forward in connecting specific gut
epithelial-neural circuits and developing the
necessary understanding to trace microbe-to-
brain communication.
Immune and neurotransmitter signaling
In addition to their actions on enteroendocrine
and neural cells, metabolites can act via GPCR
and other receptors to direct the development
and normal functioning of the mucosal immune
system; regulating the recruitment, development,
maintenance, and activation of immune cells. The
balance of dietary and bacterial metabolites is
important for maintaining immune tolerance,
and in directing inflammatory responses in
the gut.
There are three main routes by which metabolite-
immune cell interactions in the gut may be relayed to
the brain. The first is via the secretion of cytokines
and other immune signaling molecules into the
bloodstream which ultimately reach the BBB.
Breakdown of the epithelial barrier, resulting from
dysbiosis, infection, damage, or age-associated
degeneration allows ingress of bacteria, their meta-
bolites, and other components such as toxins and
lipopolysaccharides (LPS), triggering inflammatory
immune responses and enteric neuronal damage.115
If not resolved, continuous or remitting intestinal
inflammation (a hallmark of inflammatory bowel
disease) can promote a state of chronic systemic
inflammation characterized by elevated serum
TNF, IL-6, and IL-1β, disrupting the BBB by increas-
ing the permeability of the BMEC layer116 and allow-
ing solutes and toxins into the brain. Increased
systemic and brain inflammation also promotes
immune cell extravasation117 and stimulates inflam-
matory signalling by cells of the NVU and brain
microglia,118 perpetuating a vicious cycle of brain
inflammation and neurodegeneration. In vivo infec-
tion models show that elevated TNF drives brain
pathology in a Drosophila model of enterobacteria
infection-aggravated AD.119 In mice, blocking TNF
uptake at the BBB by inhibiting TNF receptor 1
(TNFR1) can reduce immune cell infiltration and
ameliorate disease severity in a model of MS.120
Metabolite-immune cell interactions, intestinal bar-
rier dysfunction, and bacterial infection can there-
fore be important early events in initiating
neurodegenerative disease by altering gut-to-brain
cytokine signaling and immune cell trafficking.
In the second route, metabolite induced secre-
tion of immune cell cytokines and neurotransmit-
ters may act locally on enteric neurons innervating
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the gut and alter vagus nerve signaling to the
brain. With advancing age, a primary risk factor
for neurodegenerative diseases, a shift in the polar-
isation of intestinal macrophages and their cyto-
kine production alters enteric neural responses to
inflammatory signals and increases apoptosis and
loss of enteric neurons.121 Loss of enteric neurons
not only alters intestinal functions but has impli-
cations for the ability of the gut to communicate
with the brain. Furthermore, the cytokine milieu
affects the functioning of enteric glial cells that
support and regulate enteric neuronal functions
by production of glial cell-derived neurotrophic
factors (GDNFs). Glial cell GDNF production in
response to microbial-immune cell signaling,122
and potentially via SCFA-GPCR activation,123,124
induces innate lymphoid type 3 (ILC3) cells to
produce IL-22, promoting protection and restora-
tion of the epithelial barrier.125 These cells are
therefore important in integrating microbial and
host signalling in neuro-immune responses in the
intestinal mucosa.
Along with immunoregulatory cytokines, bind-
ing of bacterial metabolites to intestinal cells can
also trigger the release of local peptide neurotrans-
mitters, including PYY and serotonin, for which
enteric neurons express specific receptors.126,127
For example, decarboxylation of tryptophan to
tryptamine by Clostridium sporogenes induces
enterochromaffin cells to release serotonin, which
acts on enteric neurons to stimulate gastrointest-
inal motility.128,129Serotonin is also involved in
regulating neurogenesis during development130
but detangling its role in adult neurodegeneration
is complicated by the multitude of serotonin
receptor subtypes expressed in the mammalian
brain.131 Gut microbes may also trigger neuro-
transmitter release via Toll-Like Receptor (TLR)
signaling on epithelial, immune and neuronal
cells.132,133 Finally, bacterial metabolites may act
directly as neurotransmitters, acting locally and
in the brain. Lactobacillus and Bifidobacterium
can metabolize glutamate to produce GABA,
a major inhibitory neurotransmitter of the
brain68,134 and modulator of gut functions.135
Various enteric bacteria are also able to synthesize
and release nitric oxide,136 acetylcholine,137
noradrenaline,138 and dopamine.139 The emerging
field of “psychobiotics”140,141 proposes to
manipulate these neurotransmitter-producing bac-
teria to regulate gut and brain function.
In the third route, metabolite-activated immune
cells may travel via the bloodstream to release
soluble factors at the BBB which impacts its integ-
rity and alters the inflammatory status of brain
cells. Systemic inflammation and elevated circulat-
ing TNF promote extravasation of leukocytes and
macrophages to the brain by upregulating adhe-
sion molecules, chemokines, and matrix metallo-
proteases at the BBB and in the brain,117,142 and by
downregulating tight junctions. At steady state,
during infection, and following brain injury,
T cells from the gut can traffic to the brain.143,144
Circulating immune cells may cross the BBB and
choroid plexus to enter the brain and local drain-
ing lymph nodes145,146 or infiltrate via meningeal
vascular channels.147 SCFA signaling may mitigate
some of these effects, as altered lymphocyte migra-
tion from the gut in response to SCFAs can ame-
liorate uveitis148 and modulation of the microbiota
and its metabolites can impact neuroinflamma-
tion, and neurodegeneration.
Microbiota-gut-brain pathways in
neurodegenerative disease
Multiple neurological and neurodegenerative dis-
ease are now being associated with gut dysbiosis,
following infection, inflammation or antibiotic
use, although the mechanisms of gut-brain trans-
mission of pathology have so far remained elusive.
PD is of particular interest in this regard as
a proposed etiology has developed from
a growing collection of animal and epidemiologi-
cal studies which link PD with pathogenic alpha
synuclein (αSyn) protein production and accumu-
lation in the gastrointestinal tract. A proposed
sequence of events involves age- infection-, or
dysbiosis-driven αSyn accumulation in the intes-
tine, leading to trans-synaptic transmission of
pathological forms of αSyn from enteric neurons
to the vagus nerve, and retrograde axonal trans-
port along the vagus to the brainstem.149-151 This
model draws on autopsy studies of Lewy bodies,
and observations that onset of gastrointestinal
symptoms in PD patients, and detection of patho-
logical α-synuclein (αSyn) in gastrointestinal tis-
sues in animal models of PD, are seen prior to the
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onset of motor symptoms. Also, rodent studies in
which αSyn expression was chemically induced in
enteric neurons, or in which recombinant αSyn
was delivered to the gastric and/or duodenal wall,
report subsequent αSyn detection in the vagal
nerve and multiple brain regions.152-155 The iden-
tification of αSyn also within intestinal enteroen-
docrine cells156 is interesting in light of the
recently described synaptic connections between
subsets of these cells and vagal afferents,113 pro-
viding a gut lumen-to brain communication
pathway.
What events may trigger the initial generation
of pathogenic αSyn in the gut, and whether αSyn
propagation from the intestine to the vagus and/or
brainstem occurs in humans and is causative in
human PD pathology remain unknown. While
transmission of αSyn via the vagal route has
received the most attention, gut-brain transmis-
sion by other neural pathways (e.g. the splanchnic
nerve innervating the colon, olfactory neurons157)
or by trafficking immune cells is also possible.
Moreover, vagal transmission is not absolutely
required for PD development, as vagotomy delays
but does not prevent PD-like pathology in mice153
and while some human epidemiological studies
suggest vagotomy is associated with lower risk of
developing PD,158 others do not.159,160 The human
appendix, which houses a diverse microbiome,161
and in which pathology-associated αSyn can be
also detected, has also been suggested as a site of
gastrointestinal αSyn seeding.162 While the history
of appendectomy was associated with delayed
onset of PD symptoms in a small late-onset
cohort163 a larger study found no effect,164 and
others find either no effect or a slightly increased
risk of developing PD 5–10 years post-
appendectomy.165,166 As a reservoir of microbes
and immune cells, the appendix could still have
a role in modulating PD risk by influencing micro-
bial and immune homeostasis. Given the interac-
tion between gut microbes, enteroendocrine cells,
enteric neurons and the enteric immune system
discussed above, and recent evidence that bacterial
proteins can enhance αSyn aggregation in animal
models,167 the activities of specific gut microbes or
a more general ‘microbial dysbiosis’ could
conceivably play a role in the transition from
benign to pathogenic αSyn states.
In summary, a complex interplay of signalling
between epithelial, immune, and neural cell signal-
ling networks is involved in translating microbial
metabolite changes in the gut and the brain, and
may be involved in the etiology of neurodegenerative
disease. Progress is being made in trying to dissect
these interactions, but a better understanding of
microbe-brain communication now requires cross-
disciplinary multi-organ-based investigations.
Modulation of the gut microbiota as
a potential therapeutic tool for promotion
and restoration of brain health
Disruption of the complex ecosystem of the intest-
inal microbiota is now implicated in multiple con-
ditions and diseases of both the intestine and the
brain, and some of the routes by which microbes
may act on the gut-brain axis are beginning to be
unravelled. Manipulating or shaping the micro-
biota is therefore attracting attention as a viable
strategy to prevent or treat various extra-intestinal
diseases. The beneficial effects of an ‘optimized’
gut microbiota would include immune and epithe-
lial homeostasis, enteric nervous system regula-
tion, and optimal digestion and metabolism. This
would theoretically protect against neurodegenera-
tive disease by preventing metabolic, cardiovascu-
lar and inflammatory conditions which are
associated with neurodegeneration but, as dis-
cussed above, could also protect BBB integrity
and brain function by more direct means.
Current therapeutic approaches under considera-
tion include modifying the existing microbial
composition in the gut by: altering nutrient avail-
ability to promote the growth of particular classes
or species of bacteria (prebiotics); introducing or
expanding ‘beneficial’ species (probiotics); or by
wholesale transplant of entire communities or por-
tions of communities from other intestinal donors
(faecal microbial transplantation and more selec-
tive stool transplants). Below we consider how
some of these approaches are beginning to be
tested, and the potential for their use in improving
blood-brain-barrier homeostasis and brain health.
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Promoting growth of beneficial microbes via
prebiotics
Prebiotics are non-digestible short-chain carbohy-
drates that, when ingested selectively, stimulate the
development of some health-promoting colonic
bacteria.168 The nutritional properties exhibited by
prebiotics derive from their resistance to hydrolysis
in the upper gastrointestinal tract and their fermenta-
tion in the large intestine by mainly anaerobic
bacteria.169 Common prebiotics include disaccharides
(lactulose), oligosaccharides (fructooligosaccharides,
FOS, galactooligosaccharides, GOS) and polysacchar-
ides (inulin).170 Other compounds that can also be
considered as prebiotics are resistant starches, pectin,
whole grains, and polyphenols.171 Once in the gut,
prebiotic compounds are metabolized by the host
microbiota and resulting metabolites, such as
SCFAs, act on the brain through different pathways
contributing to an effect on BBB permeability and
neurological health (described above). Several animal
studies have analyzed the effect of prebiotics on brain
function172-176 including modulating mood and stress
responses by activating or supressing the hypothala-
mic-pituitary-adrenal (HPA) or “stress” axis. Serum
and salivary cortisol are reliable indicators of HPA-
activation (stress) and can be modulated by pre- and/
or probiotics. The raised levels of circulating cortisol
in germfree rodents177 are reduced following the
administration of probiotics.178 In healthy mice, sup-
plementation with long-chain FOS or short-chain
GOS, which promote the growth of beneficial species
such as Bifidobacteria,172 decreased anxiety-related
behaviors and increased social behavior.179 Few stu-
dies investigating the benefit of prebiotics on human
brain function have been published to date, and are so
far inconclusive. One example in healthy adult volun-
teers described reduced stress response (salivary cor-
tisol awakening response) after GOS intake.180 In
preterm infants, supplementation with different pre-
biotics showed improvement in brain development
when compared to a control group.181 Synergistic
combinations of prebiotics and probiotics (synbiotics)
have been found to improve age-related memory
impairment in rats182 and are now being trialled in
human clinical studies to promote intestinal
health.183,184 One simple goal arising from such stu-
dies is devising optimized healthy diets which include
all the required nutrients and prebiotics needed to
decrease the number of harmful gut microbiota, and
to increase the concentration of microorganisms pro-
ducing metabolites which have beneficial effects on
immunologic, metabolic and brain function to
maximize health.
Changing the gut microbiota composition via
probiotics
Probiotics are non-pathogenic living microorgan-
isms added to, or naturally occurring in, food
products, that confer a health benefit to the host
when administered in adequate amounts.185
Examples include gut include species of the genera
Lactobacillus, Bifidobacterium, Lactococcus,
Streptococcus, and Enterococcus.186 There is
increasing interest in exploring the beneficial fea-
tures of next-generation probiotics or live thera-
peutic products which include species not
traditionally considered as probiotics, such as
Akkermansia muciniphila,187 Faecalibacterium
prausnitzii,188 species of the genus Bacteroides,189
and genetically modified Lactococcus strains carry-
ing beneficial traits.190 Recent evidence suggests
that probiotic bacterial viability is not necessary
to develop health-promoting effects in the host.191
The administration of inactivated probiotic micro-
organisms, known as paraprobiotics, has been
shown to confer benefits to the host without the
risk of enhanced inflammatory responses in
immunocompromised individuals.192,193 In line
with this concept, the term postbiotics, also
known as metabiotics or simply metabolites,
emerged to refer to bioactive soluble factors
secreted by live bacteria or released after bacterial
lysis, reinforcing the idea that cell viability is not
essential to induce healthy effects.191
Probiotic treatments have been associated with
modulating mood and anxiety in animal models
and humans. The first reported trial of using pro-
biotic bacteria to treat mental health conditions
was published in the early 20th century and
described the use of lactic acid bacteria to success-
fully treat melancholia and constipation.194 The
term “psychobiotics” has since been coined to
describe bacteria which, when ingested in adequate
amounts, have a positive mental health effect.140
Several human interventions provided evidence
that psychobiotics can alter mental state. The
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intake of Lactobacillus helveticus and
Bifidobacterium longum reduced 24-hour urinary
free cortisol, a biomarker for stress response, in
healthy volunteers.195 Healthy students consuming
fermented milk containing Lactobacillus casei
strain Shirota had lower plasma cortisol compared
to placebo group on the day before an
examination,196 and a probiotic strain of
Lactobacillus rhamnosus exhibited a protective
effect on symptoms of postpartum depression.197
One possible mechanism for the mood-altering
effects of psychobiotics is by enhancing produc-
tion of neurotransmitters, such as GABA and glu-
tamate which control neural excitation-inhibition
balance, and BDNF which is implicated in learning
processes and control of fear.198 Another possible
mechanism is by altering the balance of circulating
pro-and anti-inflammatory cytokines, restoring
inflammation-induced BBB permeability, prevent-
ing potentially harmful material from entering the
brain,199 and promoting mental health and psy-
chological resilience.140
Probiotic modulation has also shown promise in
alleviating symptoms of PD. Delivery of some pro-
biotic cultures has shown beneficial effects on gas-
trointestinal symptoms in PD patients,200,201 while
one study delivering a Bifidobacteria/Lactobacilli
mix found improvements in motor scores.202
Probiotics may also prove useful in treating AD.
Delivery of Bifidobacteria/Lactobacilli mixtures has
shown several benefits in mouse and rat models
of AD, including improvements in memory and
learning tests, reduced measures of oxidative stress,
reduction in histopathological markers in the
brain,203,204and restoration of neuronal cell proteo-
lytic functions.205 Some small-scale exploratory
human studies comparing AD patients before and
after probiotic supplementation, again using
Bifidobacteria/Lactobacilli mixtures, report
improved mini-mental state examination (MMSE)
scores and improvement in some metabolic and
inflammatory markers.206,207 Two recent rando-
mized, double-blinded, placebo-controlled clinical
trials show improved MMSE cores, reduced serum
C-reactive protein (an inflammatory marker) and
improved insulin metabolism in patients receiving
probiotic mixture containing Bifidobacteria and
Lactobacilli species.208,209 As with PD, the mechan-
isms of probiotic-promoted neuroprotective effects
in AD studies remain to be determined but may
reflect positive effects on gut barrier health leading
to improved immune and metabolic health (e.g.
protection against type-II diabetes, decreased sys-
temic inflammation), which in turn protects against
BBB breakdown and neural pathology.
Changing the gut microbiota via fecal microbiota
transplantation (FMT)
FMT is the therapeutic administration of fecal mate-
rial containing gut microbiota from a healthy donor
to a recipient with a dysbiosis-related condition, via
enema, nasogastric, nasoenteric or endoscopic
routes, to restore normal diversity and function in
the microbial community.210 FMT was first
described in a medical manual for emergencies writ-
ten by the Chinese alchemist Ge Hong in the fourth
century, who reported that people suffering from
food poisoning and diarrhea recovered after oral
administration of fecal suspensions (‘yellow dragon
soup’).211 A more recent and well-documented use
of FMT is the treatment of patients with Clostridium
difficile infection, with efficacy rates of approxi-
mately 90%.212 FMT has also been used to treat
ulcerative colitis but with an effectiveness of lower
than 25%.213 The overall results of several rando-
mized controlled trials using FMT to treat irritable
bowel syndrome are so far inconclusive regarding
efficacy in improving severity scores.214 Due to the
bidirectional signalling interactions along the micro-
biota-gut-brain axis, FMT has also been suggested as
a potential treatment for extra-intestinal disorders,
including neurological conditions. Bercik and
colleagues215 published one of the first studies
using FMT to modulate brain function and modu-
late host behavior in mice. They colonized germfree
BALB/c mice, usually a timid strain, with microbiota
from the more exploratory NIH Swiss strain. The
BALB/c mice displayed less timid and more explora-
tory behaviour after FMT, associated with higher
levels of BDNF in the brain. In the reverse experi-
ment, colonization of germfree NIH Swiss mice with
BALB/c microbiota reduced exploratory behavior,
suggesting the gut microbiota play a key role in
behavior.215 In support of this study, Zheng and
colleagues216 showed that germfree mice trans-
planted with microbiota from major depressive dis-
order patients displayed depression-like behavior.
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Kelly and colleagues217 also found physiological and
behavioral features of depression in microbiota-
depleted rats after transplantation with fecal micro-
biota from depressed patients, as well as
a dysregulation in tryptophan metabolism, similar
to that reported in autism, schizophrenia and neu-
rodegenerative diseases.218,219 In a disease model,
FMT from normal mice has neuroprotective effects
in a mouse model of PD, including reducing TNF-
driven neuroinflammation and increasing brain
levels of dopamine and serotonin, leading to
improvement in motor symptoms.220 Currently, stu-
dies focusing on the effect of FMT on the neurode-
generative disease in humans are lacking.
Anecdotally, neurologic improvement in one patient
with PD has been reported following FMT for
chronic constipation.221 Given the possible gut-
brain propagation of pathogenic αSyn discussed
above, the use of FMT to modulate the intestinal
production of αSyn could be protective against PD
by providing a ‘protective’ microbiota, which either
does not promote aberrant protein folding or out-
competes pathogenic strains, or by maintaining
immune, neural and epithelial barrier homeostasis
such that any aberrant protein folding in the gut
lumen is contained locally. However, safety remains
a major concern in translating FMT research to
humans. Stool donors and samples for FMT are
currently tested for different potentially pathogenic
bacteria, viruses, parasites, and other
microorganisms,222 but this is far from knowing
the complete microbial composition of the sample
to be transplanted, raising both safety concerns and
issues over how to interpret results. The delivery of
selective microbial mixtures, as in stool substitute
transplant therapy (SSTT) or microbial ecosystem
therapeutics (MET), in which purified beneficial
intestinal bacterial cultures derived from a single
healthy human donor are delivered into a patient’s
gastrointestinal tract, could minimize the potential
risk of pathogenicity, not only due to infection but
also to metabolic disease development or oncogenic
potential. By inducing large-scale shifts in the intest-
inal microbiota by methods such as FMT and SSTT,
metabolite production in the gut and subsequent
availability in circulation may also be significantly
altered. One recent study of African turquoise killi-
fish (Nothobranchius furzeri) using metabolomic
analysis of intestine, brain, liver, heart, skeletal
muscle, serum, and stool, found important meta-
bolic pathways are modified during killifish aging
and that these changes could in part be reversed by
gut microbiota transfers from young donors.223 New
work onmetabolomics will be vital to understanding
the complex metabolic interactions between host
and microbes and how metabolic profiles are asso-
ciated with health and disease. By harnessing such
methods, and combining this information with
microbial ‘omics and systems biology approaches, it
may be possible to identify beneficial vs detrimental
microbial and metabolic profiles and pathways for
gut and brain health, and to work towards optimized
personal therapies to achieve beneficial conditions
using a combination of microbial and dietary inter-
vention. These and other improvements in our
understanding of microbe–host interactions at the
gut and brain barriers will hopefully accelerate
research in the use of microbiota-modulating thera-
pies to prevent and treat neurological and neurode-
generative disease.
Conclusions
Gut microbiome research is rapidly expanding,
with recent advances in high-throughput ‘omics
technologies, providing us with a better under-
standing of the composition and functionality of
such a complex ecosystem. Further investigation
of bacterial metabolites and their effects on hor-
mone production, immune signalling, and neural
function will enable a fuller understanding of
brain responses to age- and disease-associated
alterations in the microbiota. Despite our cur-
rent limited knowledge of specific mechanisms,
dietary and microbial modulation are showing
promise as potential strategies to tackle some
neurodegenerative and neurological diseases.
A deeper understanding of gut microbial ecol-
ogy, metabolism, and signalling networks within
the host may lead to a new generation of micro-
biome-targeted strategies, both for disease treat-
ment and prevention.
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